araag2/HINT huggingface dataset:
Clinical trial NCT00080626 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed infiltrating carcinoma of the breast

               -  Unresected clinical stage T1c, T2, T3, or T4 lesion, any N

          -  Newly diagnosed disease

               -  Diagnostic mammogram and an ultrasound of the affected breast within 3 months
                  before study entry

               -  Mammogram of the contralateral breast within 6 months before study entry

          -  Clinically measurable disease

          -  Hormone receptor status:

               -  Immunohistochemical staining for estrogen and progesterone and HER2/neu receptors
                  must be obtained on initial diagnostic material

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Sex

          -  Female

        Menopausal status

          -  Not specified

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 8 g/dL

        Hepatic

          -  Bilirubin no greater than 1.5 times normal

        Renal

          -  Creatinine no greater than 1.5 times normal

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No medical condition that would put the patient at unnecessary risk of potentially
             serious complications during study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy for current breast cancer

        Endocrine therapy

          -  At least 1 month since prior tamoxifen or raloxifene for breast cancer prevention

          -  No prior endocrine therapy for current breast cancer

        Radiotherapy

          -  No prior radiotherapy for current breast cancer

        Surgery

          -  Not specified
Clinical trial NCT00030511 (phase 2, status: terminated)
Conditions: extrahepatic bile duct cancer, liver cancer
ICD codes: C24.0, D13.5, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: fluorouracil
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary or recurrent biliary duct carcinoma from the
             proximal, middle, or distal bile ducts

          -  Measurable or evaluable disease that is considered resectable

          -  No distant metastases

               -  No non-contiguous liver metastases

               -  Resectable extension into adjacent liver allowed

               -  No metastasis to peritoneal cavity

               -  No Bismuth type 4 lesion or metastasis to celiac axis or para-aortic lymph nodes

          -  No tumor encasement of portal vein or hepatic artery

          -  No gross ascites

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  No cirrhosis

          -  No active cholangitis

          -  No fever or signs of infection in biliary drainage system

          -  Measurement of C-reactive protein optimal

          -  Bilirubin less than 3 mg/dL

        Renal:

          -  Creatinine less than 1.5 mg/dL OR

          -  Creatinine clearance greater than 60 mL/min

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective barrier contraception during and for 3 months
             after study

          -  No weight loss greater than 20% ideal body weight

          -  No active duodenal or gastric ulcers

          -  No other prior or concurrent primary malignancy except adequately treated carcinoma in
             situ of the cervix or basal cell carcinoma

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  See Disease Characteristics
Clinical trial NCT00064350 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: sorafenib, placebo
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC)

          -  Disease must have progressed after at least 2 prior chemotherapy regimens for NSCLC

          -  Patients must have measurable or nonmeasurable disease

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  AST and ALT no greater than 3 times ULN (5 times ULN in patients with liver disease)

          -  Creatinine less than 1.5 times ULN or calculated creatinine clearance greater than 50
             mL/min

          -  More than 3 weeks since prior chemotherapy, radiotherapy, immunotherapy or other
             investigational drug use

          -  Recovered from all prior therapy

          -  Fertile patients must use effective contraception

          -  Age >= 18

          -  ECOG performance status of 0-1

        Exclusion Criteria:

          -  Prior primary or metastatic brain or meningeal tumors unless clinically and
             radiographically stable and off therapy for at least 2 months

          -  Active second malignancy

          -  Clinically evident congestive heart failure, serious cardiac arrhythmias, or symptoms
             of coronary heart disease

          -  Prior radiotherapy to the only site of measurable or evaluable disease unless there is
             evidence of disease progression in that site

          -  Prior exposure to a ras pathway inhibitor (e.g., farnesyl transferase inhibitor)

          -  Concurrent medications known to be metabolized by the liver with a narrow therapeutic
             index, including the following:

               -  Ketoconazole

               -  Itraconazole

               -  Quinidine

               -  Digoxin

               -  Cyclosporine

               -  Ritonavir

               -  Grapefruit products

               -  Carbamazepine

               -  Phenytoin

               -  Phenobarbital

          -  Pregnant or nursing

          -  Clinically serious active infection

          -  Medical conditions, substance abuse or psychological/social situation that would
             preclude study participation
Clinical trial NCT00418782 (phase 2, status: terminated)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: naproxen, ce-224535, placebo
SMILES: COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, COC[C@H](O)CN1C(=O)C=NN(C1=O)C1=CC=C(Cl)C(=C1)C(=O)NCC1(O)CCCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    results of interim analysis indicate lack of efficacy when compared to placebo.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Is a healthy adult 18 to 75 years of age, inclusive, in general good health and with
             diagnosis of knee OA, as determined by the American College of Rheumatology (ACR)
             clinical/radiographic classification criteria for OA of the knee.

          -  Women must be of non childbearing potential (amenorrhea for at least 1 year PLUS have
             a serum follicle stimulating hormone (FSH) level >30 IU/L, bilateral oophorectomy or
             hysterectomy), and have a confirmed negative serum pregnancy test at the screening
             visit prior to randomization.

        Exclusion Criteria:

          -  History of other diseases that may involve the study joint, including inflammatory
             joint diseases, crystalline disease, endocrinopathies, metabolic diseases, infections,
             neuropathic disorders, avascular necrosis, Paget's disease, or tumors.

          -  Women of childbearing potential, or who are pregnant or lactating.
Clinical trial NCT01068860 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus, impaired glucose tolerance
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, R73.02
Drugs: canakinumab 150 mg, placebo to canakinumab
SMILES: CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1, CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Patient must fulfill all criteria in one of the following groups:

               -  Impaired Glucose Tolerance (IGT) as diagnosed per protocol and not on an
                  anti-diabetic medicine during the study

               -  Diagnosis of Type 2 diabetes in stable treatment with metformin

               -  Diagnosis of Type 2 diabetes in stable treatment with metformin (at least 1000
                  mg/day) in combination with a sulfonylurea

               -  Diagnosis of Type 2 diabetes in stable treatment with metformin (at least 1000
                  mg/day), sulfonylurea and thiazolidinedione combination therapy

               -  Diagnosis of Type 2 diabetes in stable treatment with at least two insulin
                  injections a day with or without metformin

          2. HbA1c between 6.5% and 8%, inclusive, at Screening; this criterion does not apply to
             the IGT group

          3. Age from 18-74 years, inclusive, and of either sex

        Exclusion Criteria:

          1. Type 1 diabetes or diabetes that is a result of pancreatic injury or other secondary
             forms of diabetes

          2. History or current findings of active pulmonary disease (e.g. tuberculosis, fungal
             diseases) as defined in the protocol:

          3. Known presence or suspicion of active or recurrent bacterial, fungal or viral
             infection at the time of enrollment proven.
Clinical trial NCT01011998 (phase 2, status: withdrawn)
Conditions: chronic myelogenous leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: gleevec (imatinib), valproic acid
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Reason stopped: 
    withdrawn due to lack of accrual per center dsmp, with pi concurrence
  
Eligibility criteria:

        Inclusion Criteria:

          -  All patients, 18 years of age or older, with a diagnosis of CML.

          -  Patients must have a life expectancy of at least 12 weeks.

          -  Patients must have an ECOG performance status of 0-2.

          -  Patients must sign an informed consent.

          -  Patients should have adequate hepatic function with a total bilirubin < 2 mg/dl and
             SGOT or SGPT < two times the upper limit of normal, and adequate renal function as
             defined by a serum creatinine < 1.5 x upper limit of normal.

          -  Patients with CML in chronic phase on imatinib as first line therapy who fulfill the
             following criteria:

          -  The patient has at least two tests for quantitative reverse transcriptase polymerase
             chain reaction (RT-PCR) for bcr-abl (peripheral blood or bone marrow aspirate). The
             results of these tests should demonstrate a relative plateau in the effect of imatinib
             on the detected level of the transcript (i.e. there should less than a ½ log
             difference between the last two values). Note: Patients will be eligible if the more
             recent study is greater than the previous study by any value.

          -  The last two quantitative RT-PCR studies should be at least 3 months apart.

          -  The patient should have received at least 9 months of imatinib since the diagnosis of
             CML.

          -  The patient is tolerating imatinib without any grade 3 or greater toxicity.

        Exclusion Criteria:

          -  Pregnant women or nursing mothers are not eligible for this trial. Patients of child
             bearing potential must use adequate contraception.

          -  Patients may receive no other concurrent chemotherapy or radiation therapy during this
             trial.

          -  Patients with severe medical problems such as uncontrolled diabetes mellitus or
             cardiovascular disease or active infections are not eligible for this trial.

          -  Patients who have a hypersensitivity to valproic acid, derivatives, or any component
             of the formulation. Patients with hepatic disease or significant impairment, or urea
             cycle disorders
Clinical trial NCT01318122 (phase 2/phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: alogliptin and pioglitazone, alogliptin and pioglitazone
SMILES: CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Had completed the core phase 2/3 thiazolidine add on study.

          2. The subject was capable of understanding and complying with protocol requirements.

          3. Signed a written, informed consent form prior to the initiation of any study
             procedure.

        Exclusion Criteria:

          1. With clinical manifestation of hepatic impairment (e.g., an AST or ALT value of 2.5
             times or more of the upper reference limit at Week 8 of the core phase 2/3
             thiazolidine add on study).

          2. With clinical manifestation of renal impairment (e.g., a creatinine value of 2 mg/dL
             or more at Week 8 of the core phase 2/3 thiazolidine add on study).

          3. With a history or symptoms of cardiac failure.
Clinical trial NCT00044044 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: lurasidone 20 mg, lurasidone 40mg, lurasidone 80 mg, haloperidol 10mg, placebo
SMILES: [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  The patient has a primary diagnosis of schizophrenia

          -  The patient has been hospitalized with acute or relapsing schizophrenia within 3 weeks
             of screening

          -  The patient has had a duration of illness of at least one year.

          -  The patient has a BPRS score of at least 42 at baseline and a score of at least 4 in
             two or more items of the positive symptom subcluster on the PANSS

          -  The patient is able to remain off antipsychotic medication for a 4 day washout period

        Exclusion criteria:

          -  The patient has had psychiatric hospitalizations other than current hospitalizations
             within 1 month prior to screening.

          -  The patient is considered treatment resistant-Substance abuse-Prolactin level of > 200
             ng/mL at baseline

          -  Pregnancy
Clinical trial NCT00548184 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: lapatinib, trastuzumab, endocrine
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must be female.

          -  Signed informed consent.

          -  Locally advanced breast cancers or primary breast cancers are eligible. Locally
             advanced cancers must be of clinical and/or radiologic size >3 cm, or >2 cm with
             clinical evidence of axillary nodal involvement. (If tumors are less than 3 cm, we
             will use radiologically measured tumor size to determine the minimal tumor size for
             eligibility and in assessing tumor size during follow-up).

          -  HER2 overexpressing tumors defined as HercepTest score of 3+, or > 10% cells
             moderately or strongly HER2 positive by other methods, or Allred semi-quantitative
             score of >5, or gene amplified.

          -  Negative serum pregnancy test (HCG) within 7 days of starting study, if of
             child-bearing potential.

          -  Kidney and liver function tests - all within 1.5 times the institution's upper limit
             of normal.

          -  Performance status (WHO scale) less than 2 and life expectancy more than 6 months.

          -  Age at least 18 years.

          -  No brain or leptomeningeal disease.

          -  No previous or current malignancies at other sites within the last 5 years, with
             exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri
             and basal or squamous cell carcinoma of the skin.

        Note: The presence of pathological involvement of axillary nodes will be assessed and
        agreed upon by two investigators.

        Exclusion Criteria:

          -  Pregnancy or unwillingness to use a reliable contraceptive method in women of
             child-bearing potential.

          -  Severe underlying chronic illness or disease.

          -  Cardiomyopathy or baseline LVEF less than 50%.

          -  Other investigational drugs while on study.

          -  Severe or uncontrolled hypertension, history of congestive heart failure or severe
             coronary arterial disease.

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel. Subjects with ulcerative colitis are also
             excluded

          -  Taking any lapatinib-prohibited medication within 7 days of first dose of study
             medications. (See Prohibited Medications List in protocol.)
Clinical trial NCT00001132 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: abacavir sulfate
SMILES: NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1
Eligibility criteria:

        Inclusion Criteria

        Patients may be eligible for this study if they:

          -  Are HIV-positive.

          -  Have been taking anti-HIV therapy that includes at least 3 anti-HIV drugs and is an
             acceptable anti-HIV drug combination for 60 to 104 days before study treatment.
             Patients must not have changed any of the drugs in the 28 days before study entry.
             (This study has been changed by extending the number of days that anti-HIV therapy has
             been received.)

          -  Have a viral load greater than 500 but less than or equal to 10,000 copies/ml and have
             had a significant decrease in viral load between 49 and 84 days after starting this
             anti-HIV therapy. (This study has been changed by extending the length of time of
             viral load decrease.)

          -  Are at least 13 years old (consent of parent or guardian required if under 18).

          -  Agree to practice abstinence or use barrier method of birth control (such as condoms)
             during the study and for 3 months after.

        Exclusion Criteria

        Patients will not be eligible for this study if they:

          -  Have ever taken ABC.

          -  Have received anti-HIV therapy for more than 104 days in the past. (This study has
             been changed by extending the number of days that anti-HIV therapy has been received.)

          -  Have a fever for 7 days in the 30 days before study entry.

          -  Have cancer, including Kaposi's sarcoma, that requires chemotherapy.

          -  Have an active infection that requires treatment in the 21 days before study entry.

          -  Have any opportunistic (AIDS-related) infection or disease that requires a change in
             medication in the 14 days before study entry.

          -  Have any medical condition or history of an illness that the doctor feels would place
             them at risk or make them unable to complete the study.

          -  Are taking drugs that affect the immune system or any experimental anti-HIV drugs,
             except for their current drug combination.

          -  Are taking St. John's wort. (This study has been changed. Previously, patients taking
             St. John's wort were eligible.)

          -  Have received a vaccine in the 21 days before study entry.

          -  Are pregnant or breast-feeding.
Clinical trial NCT00216073 (phase 2, status: terminated)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: capecitabine, oxaliplatin, trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    lack of patient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of breast cancer with evidence of (1) unresectable,
             locally recurrent, or (2) metastatic disease.·

          -  HER2 gene amplification by FISH. HER protein overexpression by immunohistochemistry
             will not be sufficient for entry.·

          -  At least one measurable lesion as defined by the RECIST.

          -  Prior hormonal therapy for metastatic disease is allowed.

          -  Maximum of one prior chemotherapy regimen or trastuzumab-containing regimen for
             unresectable, locally recurrent or metastatic disease

          -  Prior radiation therapy is allowed as long as the irradiated area is not the only
             source of measurable disease.

        Exclusion Criteria:

          -  No prior therapy with capecitabine or oxaliplatin in any setting

          -  No prior therapy with other platinum compounds·

          -  No other forms of cancer therapy including radiation, chemotherapy and hormonal
             therapy within 21 days prior to beginning protocol therapy.·

          -  No prior unanticipated severe reaction to fluoropyrimidine therapy, or known
             sensitivity to 5-fluorouracil.·

          -  No prior fluoropyrimidine therapy for metastatic disease is allowed.

          -  Prior adjuvant fluoropyrimidine therapy is allowed if completed > 12 months from study
             entry.·

          -  No symptomatic brain metastasis. ·

          -  No evidence of serious concomitant systemic disorders incompatible with the study ·

          -  No peripheral neuropathy ·

          -  No major surgery within 28 days prior to beginning protocol therapy.·

          -  Negative pregnancy test·

          -  No current breastfeeding·

          -  No malabsorption syndrome·

          -  No evidence of serious concomitant systemic disorders incompatible with the study·

          -  Patients must not be treated with any of the following while on protocol therapy or
             within 28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine,
             allopurinol.